期刊文献+

“精准医疗”背景下的分子靶向药物研究——精准药物设计策略浅析 被引量:18

Contemporary Molecular Targeted Drug in the Context of “Precision Medicine”:An Attempting Discussion of “Precision Drug Design”
原文传递
导出
摘要 如何实现对肿瘤、病毒感染等严重危害人类健康的疾病的精准治疗是当前医学界的难题和研究热点。随着"精准医疗"计划的启动,当代药物设计也随之进入"精准"靶向药物分子设计时代。基于靶标结构的合理药物设计及特异性的药物递送系统是当代精准药物设计的重要方面。靶标-配体精准相互作用为基于靶标的合理药物设计奠定了理论基础;精准"制导"化学合成方法学的研究为药物合成提供了强有力的工具;灵敏、准确分子探针的研究为当代化学生物学及发现特异性的药物递送系统提供有效的辅助手段。本文从以上几方面,从药物化学的视角综述了"精准医疗"背景下的分子靶向诊疗药物研究。 How to cure serious diseases w hich do harm to the health of human being such as tumor and virus infection by "precision medicine"is alw ays a difficult problem and a research hotspot in the medical field. With the launch of "precision medicine " project,contemporary drug design has reached the new era,namely,"precise"targeted drug molecular design should be one of the key pillars of precision medicine. The structurebased rational drug design and the targeted drug delivery system are important aspects of the contemporary"precision drug design". Precise noncovalent interactions between ligands and proteins lay the theoretical foundations for structure-based rational drug design. The development of new synthetic methodologies provides a pow erful tool for drug precise synthesis,focusing both on the identification of intrinsically novel reactions,as w ell as the discovery of improved methods for carrying out existing transformations. Chemical biology has a significant role to play in the discovery and validation of new therapeutic targets. Over the past few years,manysensitive and accurate probes based on small organic molecules have demonstrated considerable promise in"precision drug design"as they provide a chemoproteomic means to confirm and quantify target engagement and selectivity of small molecule drug candidates. In the view point of medicinal chemistry,this review highlights recent advances made in contemporary molecular targeted drug design in the context of "precision medicine".
出处 《化学进展》 SCIE CAS CSCD 北大核心 2016年第9期1363-1386,共24页 Progress in Chemistry
基金 国家自然科学基金重点国际合作研究项目(No.81420108027) 国家自然科学基金面上项目(No.81573347 81273354) 山东大学青年学者未来计划(No.2016WLJH32) 山东省重点研发计划(重大关键技术)(No.2015ZDJS04001) 山东省科技发展计划项目(No.2014GSF118012)资助~~
关键词 精准医疗 分子靶向药物 精准药物设计 药物化学 探针 化学生物学 药物发现 precision medicine molecular targeted drug precision drug design medicinal chemistry probe chemical biology drug discovery
  • 相关文献

参考文献133

  • 1何明燕,夏景林,王向东.精准医学研究进展[J].世界临床药物,2015,36(6):418-422. 被引量:39
  • 2CollinsF S, Varmus H. N. Engl. J. Med., 2015, 372(9): 793. 被引量:1
  • 3汤立达(TangLD),徐为人(XuWR).现代药物与临床,2015,4:351. 被引量:1
  • 4Poot A J, van Ameijde J, Slijper M, van den Berg A, Hilhorst R, Ruijtenbeek R, Rijkers D T, Liskamp R M. Chembiochem. , 2009, 10: 2042. 被引量:1
  • 5van Wandelen L T, van Ameijde J, Mady A S, Wammes A E, Bode A, Poot A J, Ruijtnbeek R, Liskamp R M. ChemMedChem. , 2012, 7: 2113. 被引量:1
  • 6Volkamer A, Eid S, Turk S, Rippmann F, Fulle S. J. Chem. Inf. Model. , 2016, 56: 335. 被引量:1
  • 7Song Y, Zhan P, Li X, Rai D, de Clercq E, Liu X. Curr. Med. Chem., 2013, 20: 815. 被引量:1
  • 8Lucas M C, Goldstein D M, Hermann J C, Kuglstatter A, Liu W, Luk K C, Padilla F, Slade M, Villasefior A G, Wanner J, Xie W, Zhang X, Liao C. J. Med. Chem. , 2012, 55: 10414. 被引量:1
  • 9Melillo B, Liang S Y, Park J, Sehon A, Courter J R, LaLonde J M, Wendler D J, Princiotto A M, Seaman M S, Freire E, Sodroski J, Madani N, Hendrickson W A, Smith A B. ACS Med. Chem. Lett., 2016, 7: 330. 被引量:1
  • 10Zhan P, Itoh Y, Suzuki T, Liu X. J. Med. Chem. , 2015, 58: 7611. 被引量:1

二级参考文献16

  • 1Suzanne L. Topalian,F. Stephen Hodi,Julie R. Brahmer.Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. New England Journal of Homeopathy . 2012 被引量:2
  • 2Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyooka,Kazuhiko Nakagawa,Masahiro Fukuoka.Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial[J]. Lancet Oncology . 2010 (2) 被引量:8
  • 3Adrian G. Sacher,Pasi A. J?nne,Geoffrey R. Oxnard.Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non‐small cell lung cancer[J]. Cancer . 2014 (15) 被引量:1
  • 4Ingrid Torjesen.Genomes of 100?000 people will be sequenced to create an open access research resource[J]. BMJ . 2013 (nov0) 被引量:1
  • 5Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J]. Lancet Oncology . 2012 (3) 被引量:8
  • 6HelenaSkalnikova,JanMotlik,Suresh JivanGadher,HanaKovarova.Mapping of the secretome of primary isolates of mammalian cells, stem cells and derived cell lines[J]. Proteomics . 2011 (4) 被引量:1
  • 7Yunjia Chen,Peng Yu,Jingchu Luo,Ying Jiang.Secreted protein prediction system combining CJ-SPHMM, TMHMM, and PSORT[J]. Mammalian Genome . 2003 (12) 被引量:1
  • 8Kuehn Bridget M.1000 Genomes Project finds substantial genetic variation among populations. JAMA : the journal of the American Medical Association . 2012 被引量:1
  • 9Goncalo R Abecasis,Adam Auton,Lisa D Brooks.An integrated map of genetic variation from 1,092 human genomes. Nature . 2012 被引量:1
  • 10Rosenwald A,Wright G,Chan WC,et al.The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine, The . 2002 被引量:1

共引文献38

同被引文献248

引证文献18

二级引证文献88

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部